Business Wire

Eagle Genomics Secures Industrial Strategy Challenge Fund Grant to Develop Pioneering Life Sciences Data Curation Module

Del

Smart data management for life sciences company, Eagle Genomics, has today announced it has been awarded a close to £600,000 grant from Innovate UK, the UK’s innovation agency, to support the company’s ongoing commitment to radically reduce time to insight through data science.

The project which has received the grant, under the banner; ‘Increase your data's value: A value-driven semantic enrichment system to speed up scientific insight’ – will further develop the pioneering e[curate] data curation module. Using a unique combination of conversational and statistical learning, decision theory and semantic enrichment, e[curate] will enable scientists to question data with context, significantly improving relevancy and, therefore, speed to insight. Integrated as part of Eagle’s ‘e[automateddatascientist]’ platform, e[curate] will solve the constraints scientists currently experience in being able to weave and store data consistently.

In support of the project Eagle Genomics will receive a share of the £197m to be invested in healthcare and medicine through the Industrial Strategy Challenge Fund, introduced by the UK Government to help meet the ‘major industrial and societal challenges of our time’.

The impact of the e[curate] platform on life sciences research will be significant, not only in addressing the challenge of speeding up patient access to new drugs and treatments, but also in reducing the cost of bringing drugs to market.

Executive Chairman at Eagle Genomics, Anthony Finbow commented - “We are delighted to have received this Innovate UK award, in recognition of the potential of our platform to radically reduce the time and cost involved in achieving scientific insight. We’re excited about the impact this will have on drug discovery and innovation, resulting in better tailored therapeutics (precision medicines) and safer consumer products.”

The Chief Executive of the UK’s innovation agency, Innovate UK, Dr Ruth McKernan commented: “Innovate UK is proud to support Eagle Genomics in the development of the e[curate] platform which has the potential to accelerate scientific discovery, through intelligent data storage and analysis. This will speed the creation of new medicines, increasing productivity in the health and life sciences, a key aim of the Industrial Strategy Challenge Fund.”

About Eagle Genomics

Eagle Genomics is a smart data management software company helping life sciences companies conducting data intensive research to bring new candidate medicines, therapies and products to patients and customers more quickly. Its e[automateddatascientist] platform puts state of the industry data science at the fingertips of biologists to radically reduce time to cost of research, thus enabling customers to achieve drastic productivity improvements and true data driven discovery.

For more information on Eagle Genomics, please visit the company’s website, follow Eagle Genomics on Twitter (@Eaglegen) or call Eagle Genomics at +44 (0)1223 654481

About Innovate UK

Innovate UK is the UK's innovation agency. It works with people, companies and partner organizations to find and drive the science and technology innovations that will grow the UK economy.

For further information visit www.innovateuk.gov.uk.

Contact information

Eagle Genomics
Catherine Kidd
UK +44 7719 622303
USA +1 914 215 4345
catherine.kidd@eaglegenomics.com

Om Business Wire

Business Wire
Business Wire
24 Martin Lane
EC4R 0DR London

+44 20 7626 1982http://www.businesswire.co.uk

Business Wire, a Berkshire Hathaway company, is the global leader in multiplatform press release distribution.

Følg saker fra Business Wire

Registrer deg med din epostadresse under for å få de nyeste sakene fra Business Wire på epost fortløpende. Du kan melde deg av når som helst.

Siste saker fra Business Wire

Madison Realty Capital Provides $64.0 Million Construction Financing for 200 Kent Avenue Development in Williamsburg, Brooklyn17.11.2017 16:20Pressemelding

Madison Realty Capital (MRC) announced the closing of a $64.0 million construction loan for 200 Kent Avenue, a 117,326 square foot mixed-use development located in Williamsburg, Brooklyn. The retail portion of the property, which will include over 600 feet of frontage, will be anchored by a popular national grocery chain. Overall, the project will offer 50,101 square feet of retail space, 22,055 square feet of office and restaurant space, and 45,170 square feet of parking. “We continue to establish MRC as the one-stop shop for financing transitional real estate, including ground-up development deals like 200 Kent Avenue,” said Josh Zegen, Co-Founder and Managing Principal of MRC. “In this case, we’re working with a repeat MRC borrower who understands our ability to execute efficiently, given our firm’s up-to-the minute knowledge of local market conditions and non-bureaucratic approach to

Ncardia Announces Completion of €10.5M Investment Round17.11.2017 12:31Pressemelding

Ncardia, an emerging drug discovery and development stem cell technology company whose mission is to deliver cardiac and neural solutions based on its best-in-class human induced pluripotent stem cell (iPSC)-derived technology, today announced the completion of a €10.5 million series B financing round. The round was led by Épimède, a Belgium venture capital firm. Ncardia is a privately-held company with operations in Europe and the US, that produces and commercializes high-quality, fully-functional human iPSC-derived cardiovascular and neuronal cell types. Using its cell products, Ncardia develops and commercializes assay services for drug safety and efficacy testing. Additionally the company has built up a strong portfolio of patents covering the use of stem cell models for these applications. Stefan Braam, CEO of Ncardia, commented: “At Ncardia, important progress h

Double Win for Vocalink at the 2017 Payments Awards17.11.2017 09:35Pressemelding

Vocalink, a Mastercard company, was last night awarded with two prestigious awards - The Overall Winner and the Payments Infrastructure of the Year Award, for its leading technology and expertise, and in recognition for a milestone year that saw Vocalink’s solutions transform the way people and businesses move money across the globe. 2017 saw Vocalink deliver ground-breaking immediate payments solutions both in the US and Thailand as well as enabling access to the UK payments industry through their payments gateway solution PayPort. The business also saw the launch of the new image based cheque clearing system, creating a robust and more efficient system in the UK. RTP ® in the US: This week, Vocalink announced the launch of RTP® (Real-Time Payments) in the US on behalf of The Clearing House; one of the most comprehensive real-tim

Envion AG: Start-up from the Heart of Berlin Has Pioneered Decentralized Mobile Mining by Combining Blockchain with Regenerative Energy17.11.2017 09:00Pressemelding

Envion AG has created a technology for the first truly mobile data-center that uses low-priced local energy to mine a broad spectrum of cryptocurrencies (Bitcoin, Ethereum, etc.). By harvesting locally available clean energy right at the source, envion can operate at lower costs than competitors and at the same time reduces the CO2 footprint of the blockchain industry. Envion aims at decentralizing the highly-concentrated mining market (China holds 80% in Bitcoin mining) and at bringing control of the market back to the users. That’s why envion gives 100% of its mining profits back to its community. This press release features multimedia. View the full release here: http://www.businesswire.com/news/home/20171117005011/en/ Envion - World's Most Profitable Standard of Self-Expanding Crypto Infrastructure (Photo: Business Wire) Current challenges in the energy

Chugai's HEMLIBRA® Receives the World's First Regulatory Approval from FDA for Hemophilia A with Inhibitors16.11.2017 23:30Pressemelding

Chugai Pharmaceutical Co., Ltd. (TOKYO:4519) announced today that the U.S. Food and Drug Administration (FDA) has approved the bispecific antibody emicizumab (US product name: HEMLIBRA®) for routine prophylaxis to prevent or reduce the frequency of bleeding episodes in adult and pediatric patients with hemophilia A (congenital factor VIII deficiency) with factor VIII inhibitors. This represents the first regulatory approval for HEMLIBRA® around the world. The US Biologics License Application (BLA) was submitted by Genentech, a member of Roche Group. “We are pleased that HEMLIBRA, a biopharmaceutical created by Chugai scientists based on their exceptional idea, has received its first regulatory approval,” said Chugai’s President & COO, Tatsuro Kosaka. “HEMLIBRA is a first in class biopharmaceutical which is an advancement on the current limited treatment options available for pat

Pacific Drilling Receives Approval of First Day Motions16.11.2017 22:08Pressemelding

Pacific Drilling S.A. (OTCPink: PACDQ) (“Pacific Drilling” or the “Company”) today announced that the United States Bankruptcy Court for the Southern District of New York has granted the relief requested by the Company in certain first day motions related to ordinary course business activities, subject to certain modifications at the request of the Court, the United States Trustee and stakeholders. The approved motions give us the authority to, among other things, continue to pay employee wages and benefits without interruption, to utilize our current cash management system, and to pay certain foreign and critical vendors for goods and services provided prior to the petition date. All vendors will be paid in full and in cash on normal payment terms for all goods and services provided on or after the petition date. Paul Reese, Chief Executive Officer of Pacific Drilling, said, “With the

I vårt presserom finner du alle våre siste saker, kontaktpersoner, bilder, dokumenter og annen relevant informasjon om oss.

Besøk vårt presserom